The Disease Activity Score in 28 joints in rheumatoid arthritis and psoriatic arthritis patients

被引:29
作者
Leeb, Burkhard F.
Andel, Ingrid
Sautner, Judith
Fassl, Christian
Nothnagl, Thomas
Rintelen, Bernhard
机构
[1] Humanisklinikum Lower Austria, Lower Austrian Ctr Rheumatol, Dept Med 2, A-2000 Stockerau, Austria
[2] Karl Landsteiner Inst Clin Rheumatol, Klinikum Lower Austria, Lower Austrian Ctr Rheumatol, Stockerau, Austria
来源
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH | 2007年 / 57卷 / 02期
关键词
rheumatoid arthritis; psoriatic arthritis; disease activity measurement;
D O I
10.1002/art.22531
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To assess the factorial structure of the Disease Activity Score including a 28-joint count (DAS28) if applied in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Methods. DAS28 values from 85 consecutive PsA outpatients and 2 RA patient cohorts comprising 85 patients each were compared. The first RA cohort (RA1) consisted of age- and sex-matched patients seen during the same period as the patients with PsA. The first 85 RA outpatients from September 2003 were included in the second cohort (RA2). Item weighting, factor loading, and internal consistency were assessed by factor analysis, principal component analysis, and calculation of Cronbach's alpha. Results. The mean +/- SD DAS28 scores of patients in the PsA, RA1, and RA2 cohorts were 3.2 +/- 1.31, 3.21 +/- 1.45, and 3.79 +/- 1.44, respectively. A significant difference between the PsA and RA2 cohorts was found for DAS28 (P = 0.0063), swollen joint count (P = 0.007), and patient's global assessment (P < 0.001), but not for erythrocyte sedimentation rate. Internal consistency of the DAS28 in patients with PsA was considerably lower, item weighting showed remarkable differences, and factor analysis revealed that the DAS28 constitutes a bidimensional instrument in patients with PsA, whereas in both RA cohorts it appeared to be monodimensional. Conclusion. With respect to its statistical properties, the DAS28 proved to be considerably different in PsA compared with RA. Therefore its application for disease activity assessment in patients with PsA cannot be recommended without a formal validation procedure.
引用
收藏
页码:256 / 260
页数:5
相关论文
共 23 条
[1]   Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis - Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) [J].
Antoni, CE ;
Kavanagh, A ;
Kirkham, B ;
Tutuncu, Z ;
Burmester, GR ;
Schneider, U ;
Furst, DE ;
Molitor, J ;
Keystone, E ;
Gladman, D ;
Manger, B ;
Wassenberg, S ;
Weier, R ;
Wallace, DJ ;
Weisman, MH ;
Kalden, JR ;
Smolen, J .
ARTHRITIS AND RHEUMATISM, 2005, 52 (04) :1227-1236
[2]  
ARNETT FC, 1987, ARTHRITIS RHEUM, V31, P315
[3]   A role for sex steroids in autoimmune diseases - A working hypothesis and supporting data [J].
Castagnetta, L ;
Granata, OM ;
Traina, A ;
Cocciadiferro, L ;
Saetta, A ;
Stefano, R ;
Cutolo, M ;
Carruba, G .
NEUROENDOCRINE IMMUNE BASIS OF THE RHEUMATIC DISEASES II, PROCEEDINGS, 2002, 966 :193-203
[4]   Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis - A Department of Veterans Affairs cooperative study [J].
Clegg, DO ;
Reda, DJ ;
Mejias, E ;
Cannon, GW ;
Weisman, MH ;
Taylor, T ;
BudimanMak, E ;
Blackburn, WD ;
Vasey, FB ;
Mahowald, ML ;
Cush, JJ ;
Schumacher, HR ;
Silverman, SL ;
Alepa, FP ;
Luggen, ME ;
Cohen, MR ;
Makkena, R ;
Haakenson, CM ;
Ward, RH ;
Manaster, BJ ;
Anderson, RJ ;
Ward, JR ;
Henderson, WG .
ARTHRITIS AND RHEUMATISM, 1996, 39 (12) :2013-2020
[5]   Serum levels of IL-10, IL-6, IL-1ra, and sIL-2R in patients with psoriatic arthritis [J].
Elkayam, O ;
Yaron, I ;
Shirazi, I ;
Yaron, M ;
Caspi, D .
RHEUMATOLOGY INTERNATIONAL, 2000, 19 (03) :101-105
[6]   THE AMERICAN-COLLEGE-OF-RHEUMATOLOGY PRELIMINARY CORE SET OF DISEASE-ACTIVITY MEASURES FOR RHEUMATOID-ARTHRITIS CLINICAL-TRIALS [J].
FELSON, DT ;
ANDERSON, JJ ;
BOERS, M ;
BOMBARDIER, C ;
CHERNOFF, M ;
FRIED, B ;
FURST, D ;
GOLDSMITH, C ;
KIESZAK, S ;
LIGHTFOOT, R ;
PAULUS, H ;
TUGWELL, P ;
WEINBLATT, M ;
WIDMARK, R ;
WILLIAMS, HJ ;
WOLFE, F .
ARTHRITIS AND RHEUMATISM, 1993, 36 (06) :729-740
[7]  
Furst DE, 2002, ANN RHEUM DIS, V61, P2
[8]  
HAIR JF, 1995, MULTIVARIATE DATA AN
[9]   Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis - A multinational, double-blind, randomized, placebo-controlled clinical trial [J].
Kaltwasser, JP ;
Nash, P ;
Gladman, D ;
Rosen, CF ;
Behrens, F ;
Jones, P ;
Wollenhaupt, J ;
Falk, FG ;
Mease, P .
ARTHRITIS AND RHEUMATISM, 2004, 50 (06) :1939-1950
[10]   Alefacept treatment in psoriatic arthritis - Reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis [J].
Kraan, MC ;
van Kuijk, AWR ;
Dinant, HJ ;
Goedkoop, AY ;
Smeets, TJM ;
de Rie, MA ;
Dijkmans, BAC ;
Vaishnaw, AK ;
Bos, JD ;
Tak, PP .
ARTHRITIS AND RHEUMATISM, 2002, 46 (10) :2776-2784